Questions

Answers

1. Fluorodeoxyglucose positron emission tomography (FDG PET) has limitations in detecting breast carcinoma in which of the following:

A. tumors smaller than 1 cm

B. well-differentiated tumors (tubular carcinoma, and carcinoma in situ)

C. lobular carcinoma

D. all of the above

E. none of the above

For questions 2 through 5, match the statement with the appropriate choice by choosing among the following: better overall survival and relapse-free rate; PET not sensitive in detecting; more aggressive tumor; differentiation of malignant tumor from benign lesion with 90% accuracy.

1. D, all of the above

2. tumor less than 1 cm, well-differentiated subtype (tubular carcinima, carcinoma in situ), and lobular carcinoma

2. PET not sensitive in detecting

3. higher FDG uptake

3. more aggressive tumor

4. FDG PET with standard uptake value (SUV) over 2.5 to 3.0

4. differentiation of malignant tumor from benign lesion with 90% accuracy

5. lower FDG uptake tumor

5. better overall survival and relapse-free rate

6. True or false: In axillary node staging, FDG PET sensitivity is high enough to replace nodal sampling using ^99mTc–sulfur colloid or blue dye sentinel node mapping.

6. false

7. The sensitivity of FDG PET in detecting axillary lymph node metastasis depends primarily on the sizes and numbers of nodes involved. For early-stage breast carcinoma, the sensitivity for detecting axillary adenopathy is in the range of:

A. 20% to 50%

B. 40% to 60%

C. 50% to 70%

D. 60% to 80%

E. 80% to 95%

7. A, 20% to 50%

8. In cases of breast carcinoma metastasis to bone, which of the following statements are true? (Choose as many as apply.)

A. FDG PET detects more metastasis than a bone scan.

B. Bone scans detect more metastasis than FDG PET.

C. Bone scans detect more blastic metastasis than FDG PET.

D. FDG PET detects more lytic metastasis than a bone scan.

E. FDG PET and bone scans are equally sensitive in detecting bone marrow metastasis.